三氟甲基
化学
敌手
哒嗪
效力
药代动力学
博莱霉素
配体效率
嘧啶
立体化学
受体
药理学
生物化学
体外
配体(生物化学)
内科学
医学
有机化学
化疗
烷基
作者
Oscar Mammoliti,Adeline Palisse,Caroline Joannesse,Sandy El Bkassiny,Brigitte Allart,Alex Jaunet,Christel J. Menet,Beatrice Coornaert,Kathleen Sonck,Inge Duys,Philippe Clément-Lacroix,Line Oste,Monica Borgonovi,Emanuelle Wakselman,Thierry Christophe,Nicolas Houvenaghel,Mia Jans,Bertrand Heckmann,Laurent Sanière,Reginald Brys
标识
DOI:10.1021/acs.jmedchem.1c00138
摘要
Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI